SG11201507276UA - Improved methods of use for recombinant human secretoglobins - Google Patents

Improved methods of use for recombinant human secretoglobins

Info

Publication number
SG11201507276UA
SG11201507276UA SG11201507276UA SG11201507276UA SG11201507276UA SG 11201507276U A SG11201507276U A SG 11201507276UA SG 11201507276U A SG11201507276U A SG 11201507276UA SG 11201507276U A SG11201507276U A SG 11201507276UA SG 11201507276U A SG11201507276U A SG 11201507276UA
Authority
SG
Singapore
Prior art keywords
recombinant human
improved methods
secretoglobins
human secretoglobins
methods
Prior art date
Application number
SG11201507276UA
Inventor
Aprile L Pilon
Melissa E Winn
John K Zehmer
Original Assignee
Clarassance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clarassance Inc filed Critical Clarassance Inc
Publication of SG11201507276UA publication Critical patent/SG11201507276UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/06Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
SG11201507276UA 2013-03-15 2014-03-16 Improved methods of use for recombinant human secretoglobins SG11201507276UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/843,289 US20140274915A1 (en) 2013-03-15 2013-03-15 Methods of Use for Recombinant Human Secretoglobins
PCT/US2014/030101 WO2014145357A2 (en) 2013-03-15 2014-03-16 Improved methods of use for recombinant human secretoglobins

Publications (1)

Publication Number Publication Date
SG11201507276UA true SG11201507276UA (en) 2015-10-29

Family

ID=51529893

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507276UA SG11201507276UA (en) 2013-03-15 2014-03-16 Improved methods of use for recombinant human secretoglobins

Country Status (15)

Country Link
US (4) US20140274915A1 (en)
EP (1) EP2968464B1 (en)
JP (1) JP6513632B2 (en)
KR (1) KR20160011621A (en)
CN (1) CN105722524B (en)
AU (1) AU2014233116A1 (en)
BR (1) BR112015021265A2 (en)
CA (1) CA2907395A1 (en)
ES (1) ES2883933T3 (en)
IL (1) IL241418A0 (en)
MX (1) MX2015013091A (en)
RU (1) RU2662665C2 (en)
SG (1) SG11201507276UA (en)
UA (1) UA118756C2 (en)
WO (1) WO2014145357A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274915A1 (en) * 2013-03-15 2014-09-18 Clarassance, Inc. Methods of Use for Recombinant Human Secretoglobins
WO2016205430A1 (en) * 2015-06-15 2016-12-22 Therabron Therapeutics, Inc. Recombinant human cc10 protein facilitates repair and protects against damage to the respiratory epithelium due to exposure to both cigarette and other smoke
WO2018178051A1 (en) * 2017-03-28 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Scgb1a1 polymorphism for the prediction and therapy or prevention of primary graft dysfunction
WO2019143934A1 (en) 2018-01-19 2019-07-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cancer activity of scbg3a2 and lps
KR20200138684A (en) * 2020-11-17 2020-12-10 김유신 eco-friendly hot steam soil sterilizer with soil shredder
WO2023212398A1 (en) * 2022-04-29 2023-11-02 Apc Research Assets Llc Secretoglobins for suppression of antibody responses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US20030008816A1 (en) 1997-05-28 2003-01-09 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20040047857A1 (en) 1997-05-28 2004-03-11 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
WO2000009741A1 (en) 1998-08-13 2000-02-24 The Trustees Of The University Of Pennsylvania Method of identifying proteins
US6953666B1 (en) 1998-11-06 2005-10-11 Emory University Biomarkers for oxidative stress
WO2004101824A1 (en) * 2003-05-14 2004-11-25 Shionogi & Co., Ltd. Method of detecting chronic obstructive pulmonary disease
US7655413B2 (en) * 2003-06-26 2010-02-02 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
WO2005048993A2 (en) 2003-11-14 2005-06-02 Alza Corporation Minimization of drug oxidation in drug irradiated excipients formulations
US20060275794A1 (en) * 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
JP2007059191A (en) 2005-08-24 2007-03-08 Kazuo Kono Illumination apparatus driving circuit
WO2008039941A2 (en) * 2006-09-27 2008-04-03 The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services Scgb3a2 as a growth factor and anti-apoptotic agent
US20090004684A1 (en) 2007-05-23 2009-01-01 Claudia Susanne Maier Compositions and Methods for Detection and Quantification of Protein Oxidation
CN102834115B (en) 2009-10-15 2015-01-14 克拉莱森公司 Recombinant human CC10 protein for treatment of influenza
RU2439569C1 (en) * 2010-11-12 2012-01-10 Федеральное государственное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения и социального развития Российской Федерации Method of predicting bronchopulmonary displasia in children with inherent pneumonia
US20140274915A1 (en) 2013-03-15 2014-09-18 Clarassance, Inc. Methods of Use for Recombinant Human Secretoglobins

Also Published As

Publication number Publication date
US20180244735A1 (en) 2018-08-30
JP6513632B2 (en) 2019-05-15
RU2662665C2 (en) 2018-07-26
US20140274915A1 (en) 2014-09-18
US10556938B2 (en) 2020-02-11
ES2883933T3 (en) 2021-12-09
EP2968464A2 (en) 2016-01-20
BR112015021265A2 (en) 2017-10-10
CN105722524B (en) 2020-02-21
WO2014145357A3 (en) 2014-12-31
AU2014233116A1 (en) 2015-09-24
MX2015013091A (en) 2016-10-07
US20160159870A1 (en) 2016-06-09
RU2015144359A (en) 2017-04-25
EP2968464A4 (en) 2016-11-09
EP2968464B1 (en) 2021-05-05
US20200262878A1 (en) 2020-08-20
WO2014145357A2 (en) 2014-09-18
UA118756C2 (en) 2019-03-11
CA2907395A1 (en) 2014-09-18
US9765127B2 (en) 2017-09-19
CN105722524A (en) 2016-06-29
IL241418A0 (en) 2015-11-30
US11512121B2 (en) 2022-11-29
JP2016520531A (en) 2016-07-14
KR20160011621A (en) 2016-02-01

Similar Documents

Publication Publication Date Title
IL287516A (en) Therapeutic uses of empagliflozin
HRP20190101T1 (en) Therapeutic uses of empagliflozin
HK1213818A1 (en) Therapeutic uses of empagliflozin
GB202005995D0 (en) Patient interface and aspects thereof
AU357213S (en) Patient interface
PT2922514T (en) Bi-radial patient interface
AU353287S (en) Patient interface
AU353289S (en) Patient interface
EP2999474A4 (en) Therapeutic and method of use
PL2981271T3 (en) Therapeutic uses of empagliflozin
PT3071247T (en) Device for the construction of skin
IL241418A0 (en) Title improved methods of use for recombinant human secretoglobins
GB201308440D0 (en) Therapeutic
PL2988659T3 (en) Improved methods of tissue characterization
HK1219962A1 (en) Human anti-il-32 antibodies -32
GB201318668D0 (en) Sonosensitive therapeutic
HK1220127A1 (en) Treatment of autoimmune diseases
PL3071575T3 (en) Preparation of normorphinans
AU354914S (en) Patient interface
AU354913S (en) Patient interface
AU353572S (en) Patient interface
EP2996684A4 (en) Therapeutic methods
GB201320349D0 (en) New therapeutic use
GB201321628D0 (en) Treatment of disease